Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

BACKGROUND: Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) improve survival in castration-resistant prostate cancer (CRPC). However, which agent is better for patients with CRPC remains unclear. OBJECTIVE: To evaluate whether ENZ or ABI is better as first-line treatment for CRPC. DESIGN,...

Descripción completa

Detalles Bibliográficos
Autores principales: Izumi, Kouji, Shima, Takashi, Mita, Koji, Kato, Yuki, Kamiyama, Manabu, Inoue, Shogo, Tanaka, Nobumichi, Hoshi, Seiji, Okamura, Takehiko, Yoshio, Yuko, Enokida, Hideki, Chikazawa, Ippei, Kawai, Noriyasu, Hashimoto, Kohei, Fukagai, Takashi, Shigehara, Kazuyoshi, Takahara, Shizuko, Kadono, Yoshifumi, Mizokami, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257638/
https://www.ncbi.nlm.nih.gov/pubmed/35813251
http://dx.doi.org/10.1016/j.euros.2022.04.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257638/
https://www.ncbi.nlm.nih.gov/pubmed/35813251
http://dx.doi.org/10.1016/j.euros.2022.04.016

Ejemplares similares